Recombinant plant-derived pharmaceutical proteins: current technical and economic bottlenecks.
about
Plants as Factories for Human Pharmaceuticals: Applications and ChallengesAnti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Comparative whole-genome analyses of selection marker-free rice-based cholera toxin B-subunit vaccine lines and wild-type lines.Efficiency to Discovery Transgenic Loci in GM Rice Using Next Generation Sequencing Whole Genome Re-sequencingProtein freeze concentration and micro-segregation analysed in a temperature-controlled freeze container.Moss-made pharmaceuticals: from bench to bedside.Pneumatic hydrodynamics influence transplastomic protein yields and biological responses during in vitro shoot regeneration of Nicotiana tabacum callus: Implications for bioprocess routes to plant-made biopharmaceuticals.Functionalized Graphene Oxide with Chitosan for Protein Nanocarriers to Protect against Enzymatic Cleavage and Retain Collagenase Activity.Rice seed for delivery of vaccines to gut mucosal immune tissues.Chlorella species as hosts for genetic engineering and expression of heterologous proteins: Progress, challenge and perspective.Expression and functional evaluation of biopharmaceuticals made in plant chloroplasts.Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana.Reducing biomass recalcitrance by heterologous expression of a bacterial peroxidase in tobacco (Nicotiana benthamiana).Companion Protease Inhibitors for the In Situ Protection of Recombinant Proteins in Plants.Minimally processed crude leaf extracts of containing recombinant foot and mouth disease virus-like particles are immunogenic in miceFactorial and Economic Evaluation of an Aqueous Two-Phase Partitioning Pilot Plant for Invertase Recovery From Spent Brewery Yeast
P2860
Q26775069-A72DC55C-B43B-422E-976D-B63B30A7E4E0Q30252022-ACE581D7-247B-4A13-895C-F248CAC14AD1Q35555582-8C779483-A410-4892-A620-D2563EF9C7C5Q36216109-ACED9E56-8EB6-4301-8490-B7F665F952A0Q36408658-0D2B4C93-E843-4091-BB8D-AD9E1D1093B7Q36530505-387E208B-AB7A-4245-A49F-3806F5C0DEFFQ37573499-514AD1D8-0001-4308-BB7F-4C5874075B72Q37635372-4DDDF86F-98BB-46CF-BB8E-39C632B75EC7Q38534952-E413DCC2-6CD5-4557-BFED-5019FD7D1418Q38837138-432EEFF2-C806-48BF-B26D-67003C0F8464Q39147640-22A4119C-A9F5-4DD6-A938-2A5BB0F1F0F0Q40097092-3D751046-4964-495F-BBBF-258C47EA3550Q47125715-B8A07E4C-BF1E-400C-9F8F-E26B28DA8FF8Q51626860-70C4B722-4E4C-4852-882B-1CDA045874FBQ57489969-3BBB7DF3-FBEB-4FE8-B0DC-FB46EACCC6C0Q58586207-63653759-9E5B-448B-8FCA-9717F8923442
P2860
Recombinant plant-derived pharmaceutical proteins: current technical and economic bottlenecks.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Recombinant plant-derived phar ...... ical and economic bottlenecks.
@en
type
label
Recombinant plant-derived phar ...... ical and economic bottlenecks.
@en
prefLabel
Recombinant plant-derived phar ...... ical and economic bottlenecks.
@en
P2860
P1476
Recombinant plant-derived phar ...... nical and economic bottlenecks
@en
P2093
Maite Sabalza
P2860
P2888
P304
P356
10.1007/S10529-014-1621-3
P577
2014-07-22T00:00:00Z